KFDA to elucidate possible link between sibutramine therapy and adverse events

Published: 2010-04-14 06:58:00

Updated: 2010-04-14 06:58:00

The Korea Food and Drug Administration says it will reach a conclusion on safety of sibutramine by next month after full review of clinical data from the Sibutramine Cardiovascular Morbidity/Mortality Outcomes in Overweight or Obese Subjects at Risk for CVD (SCOUT) trial, which was submitted by A...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK